New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following “Positive Feedback”
Advertisement
Big news out of New Jersey this morning as a %Biotech company said it received “positive feedback” from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC, according to a release.
Advertisement
Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.
Traders were in a rush to grab up shares of %Tharimmune Inc. (Nasdaq: $THAR ) following the news, with shares of this micro cap currently trading around $4.08/share (+100.99%) at the time of writing. This move was a strong breakout of a multi-month downtrend that this stock has been stuck in, which could be an indication of things to come. Keep your eye on this one!
Advertisement
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers.
Invezz.com partners with a wide range of publishers to ensure our readers get the most up to date news. The original press release was published here.
This article is a collaboration between our Editors and our Partners, and it may contain sponsored advertising content and links. The content is not intended as financial advice and is for informational purposes only.
Advertisement
Want easy-to-follow crypto, forex & stock trading signals? Make trading simple by copying our team of pro-traders. Consistent results. Sign-up today at Invezz Signals™.